

# Enhancement of the *in vivo* persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA

Yun Bai<sup>1</sup>, Shifeng Kan<sup>1</sup>, Shixin Zhou<sup>1</sup>, Yuting Wang<sup>1</sup>, Jun Xu<sup>2</sup>, John P Cooke<sup>4</sup>, Jinhua Wen<sup>1</sup>, Hongkui Deng<sup>1,2,3</sup>

<sup>1</sup>Department of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Center for Molecular and Translational Medicine, Peking University Health Science Center, Beijing, China; <sup>2</sup>The MOE Key Laboratory of Cell Proliferation and Differentiation, College of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China; <sup>3</sup>Shenzhen Stem Cell Engineering Laboratory, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China; <sup>4</sup>Department of Cardiovascular Sciences, Center for Cardiovascular Regeneration, The Methodist Hospital Research Institute, Houston, TX, USA

*Cell Discovery* (2016) **2**, 15052; doi:10.1038/celldisc.2015.52; published online 26 January 2016

---

**Correction to:** *Cell Discovery* (2015) **1**, 15040; doi:10.1038/celldisc.2015.40; published online 8 December 2015

In the initial published version of this article, an error was made during the description of Materials and Methods. In the section ‘*In vivo* bioluminescence of tumors’, we mentioned ‘Severe combined immune deficiency NPG/Vst mice obtained from the VITALSTART’. However, the name of the company is VITALSTAR, so we want to correct it. This mistake in Materials and Methods does not affect the description of the results in the paper or the conclusions of our paper. We also deeply apologize for any inconvenience that may have been caused by our error.